好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A case of aggressive motor neuron disease without profound loss of motor neuron cells
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:30 PM-6:30 PM)
12-001

We report a case of amyotrophic lateral sclerosis - ‘fused in sarcoma’(ALS-FUS)subtype with a striking disparity between its clinical manifestation and histopathologic findings.

ALS is a neurodegenerative disorder characterized by loss of upper and lower motor neurons, resulting in progressive weakness, atrophy, and paralysis of skeletal muscles. It is a clinical syndrome named for its neuropathological hallmark – degeneration of motor neurons in the spinal anterior horns with TDP43 & ubiquitinated inclusions, accompanied by loss of axons in the lateral columns. 

 

We reviewed a case of a29-year-old male who presented with rapidly progressive severe neck weakness, asymmetrical bilateral upper extremity weakness, profound muscle wasting, bulbar dysfunction, and weight loss.

Within one year, his speech became unintelligible, he became gastrostomy and tracheostomy/ventilator dependent, and wheelchair bound. Electrophysiology suggested a motor neuron disease. Whole exome sequencing revealed a heterozygous pathogenic variant in the ‘fused in sarcoma gene (FUS), c.1574C>T, p.R525L, which was inherited in an autosomal dominant pattern,  consistent with the diagnosis of ALS. Autopsy revealed extensive denervation atrophy of skeletal musculature. Surprisingly, there was only mild patchy depletion of motor neurons within the cervical cord anterior horns. TDP43 inclusions was absent. Increased expression of FUSmutation product (cytoplasmic inclusions) was demonstrated within anterior horn neurons of the upper, mid, lower cervical segments, and glial cells. The most prominent finding was a disparity between profound neck muscle weakness, atrophy and relatively low-grade anterior horn cell loss in the cervical cord.

This s a case of a rare ALS-FUS subtype with an unusually aggressive clinical course and absent TDP43 inclusion. The disparity between phenotype and relatively preserved motor neuron cell population may suggest a secondary cause of anterior horn cell dysfunction. In addition, we noted increased FUS expression in glial cells, a feature that has not been well documented in such cases. 


Authors/Disclosures
Yin A. Liu, MD, FAAN (UC Davis)
PRESENTER
Dr. Liu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Liu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx.
No disclosure on file
No disclosure on file
Jeffrey Rosenfeld, MD, PhD, FAAN (Loma Linda University School Medicine - NEUROLOGY) Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ML Biosolutions. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Catalyst. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexion. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurizon. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serano/EMD. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anelixis. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Strongbridge Pharma. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Rosenfeld has received research support from MT Pharma. The institution of Dr. Rosenfeld has received research support from Alexion. The institution of Dr. Rosenfeld has received research support from Healey ALS Trial Center Mass General.